The association between Helicobacter pylori with nonalcoholic fatty liver disease assessed by controlled attenuation parameter and other metabolic factors

• Published in: PloS one Vol. 16; no. 12; p. e0260994
• Main Authors: Han, Yoo Min, Lee, Jooyoung, Choi, Ji Min, Kwak, Min-Sun, Yang, Jong In, Chung, Su Jin, Yim, Jeong Yoon, Chung, Goh Eun
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 13.12.2021; Public Library of Science (PLoS)
• Subjects: Asymptomatic; Attenuation; Biology and Life Sciences; Blood pressure; Body mass; Body mass index; Body size; Cholesterol; Cohort Studies; Confidence intervals; Diabetes; Disease control; Elasticity Imaging Techniques; Evaluation; Fasting; Fatty liver; Female; Gastroenterology; Glucose; Health aspects; Helicobacter Infections - complications; Helicobacter pylori; Hemoglobin; Hepatitis; Hepatology; High density lipoprotein; Hospitals; Humans; Hypertension; IgG antibody; Immunoassay; Immunoglobulin G; Infections; Internal medicine; Laboratories; Liver; Liver diseases; Male; Medical screening; Medicine; Medicine and Health Sciences; Metabolic syndrome; Methods; Middle Aged; Multivariate analysis; Non-alcoholic Fatty Liver Disease - microbiology; Obesity; Parameters; Phosphatase; Phosphate esters; Population; Retrospective Studies; Risk factors; Serology; Serum levels; Stiffness; Triglycerides; South Korea; France; Paris France
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0260994

Existing studies have suggested an association between Helicobacter pylori (Hp) infection and nonalcoholic fatty liver disease (NAFLD). We investigated the relationship between Hp infection and NAFLD using controlled attenuation parameter (CAP) and other metabolic factors. We conducted a retrospective cohort study of apparently healthy individuals who underwent liver Fibroscan during health screening tests between January 2018 and December 2018. Diagnosis of Hp infection was based on a serum anti-Hp IgG antibody test and CAP values were used to diagnose NAFLD. Among the 1,784 subjects (mean age 55.3 years, 83.1% male), 708 (39.7%) subjects showed positive results of Hp serology. In the multivariate analysis, obesity (body mass index ≥25) (odds ratio [OR] 3.44, 95% confidence interval [CI] 2.75-4.29), triglyceride (OR 2.31, 95% CI 1.80-2.97), and the highest tertile of liver stiffness measurement (OR 2.08, 95% CI 1.59-2.71) were found to be associated with NAFLD, defined by CAP ≥248 dB/m, while Hp-seropositivity showed no association with NAFLD. Serum levels of HDL cholesterol significantly decreased in subjects with Hp-seropositivity compared to HP-seronegativity in both groups with and without NAFLD (P<0.001). While Hp seropositivity was not associated with CAP-defined NAFLD, serum HDL cholesterol level were negatively associated with Hp-seropositivity in both groups with and without NAFLD. Further clinical and experimental studies are necessary to determine the association between Hp infection and NAFLD.